

Michelle A Petri

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7870857/michelle-a-petri-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

313 papers	26,108 citations	78 h-index	157 g-index
356 ext. papers	31,948 ext. citations	6.1 avg, IF	6.98 L-index

#	Paper	IF	Citations
313	Salivary anti-nuclear antibody (ANA) mirrors serum ANA in systemic lupus erythematosus.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 3	5.7	1
312	The CD6/ALCAM pathway promotes lupus nephritis via T cell-mediated responses.. <i>Journal of Clinical Investigation</i> , 2022 , 132,	15.9	2
311	Treatment Patterns and Clinical Characteristics of Patients with Systemic Lupus Erythematosus and Musculoskeletal Symptoms: A Retrospective, Observational Study.. <i>Advances in Therapy</i> , 2022 , 1	4.1	1
310	Drug monitoring in systemic lupus erythematosus.. <i>Current Opinion in Pharmacology</i> , 2022 , 64, 102225	5.1	
309	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , 2021 , 73, 1231-1235	4.7	10
308	Urine Proteomics and Renal Single Cell Transcriptomics Implicate IL-16 in Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2021 ,	9.5	1
307	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. <i>Annals of the Rheumatic Diseases</i> , 2021 , ,	2.4	4
306	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	7
305	Deconvoluting virome-wide antibody epitope reactivity profiles.. <i>EBioMedicine</i> , 2021 , 75, 103747	8.8	3
304	Clinical and laboratory characteristics of Brazilian versus non-Brazilian primary antiphospholipid syndrome patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Advances in Rheumatology</i> , 2021 , 61, 64	3	
303	Cachexia in Systemic Lupus Erythematosus: Risk Factors and Relation to Disease Activity and Damage. <i>Arthritis Care and Research</i> , 2021 , 73, 1577-1582	4.7	2
302	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , 2021 , 73, 1789-1795	4.7	2
301	Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus. <i>Rheumatology</i> , 2021 , 60, 3770-3777	3.9	7
300	Systemic lupus Erythematosus and geomagnetic disturbances: a time series analysis. <i>Environmental Health</i> , 2021 , 20, 28	6	1
299	Transcription Factor Activity Inference in Systemic Lupus Erythematosus. <i>Life</i> , 2021 , 11,	3	1
298	Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	4
297	Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update. <i>Current Rheumatology Reports</i> , 2021 , 23, 45	4.9	3

296	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021 , 30, 1283-1288	2.6	2
295	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , 2021 , 73, 2293-2302	9.5	2
294	Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2021 , 73, 997-1004	9.5	7
293	Risk Factors For Infection And Health Impacts Of The Covid-19 Pandemic In People With Autoimmune Diseases. <i>Clinical Infectious Diseases</i> , 2021 ,	11.6	7
292	Risk of Renal Failure Within 10 or 20 Years of Systemic Lupus Erythematosus Diagnosis. <i>Journal of Rheumatology</i> , 2021 , 48, 222-227	4.1	2
291	Predictors of the start of declining eGFR in patients with systemic lupus erythematosus. <i>Lupus</i> , 2021 , 30, 15-24	2.6	0
290	Reply. <i>Arthritis and Rheumatology</i> , 2021 , 73, 359	9.5	
289	Antiphospholipid Antibody Profile Stability Over Time: Prospective Results From the APS ACTION Clinical Database and Repository. <i>Journal of Rheumatology</i> , 2021 , 48, 541-547	4.1	4
288	Sub-setting systemic lupus erythematosus by combined molecular phenotypes defines divergent populations in two phase III randomized trials. <i>Rheumatology</i> , 2021 , 60, 5390-5396	3.9	
287	RISK FACTORS FOR INFECTION AND HEALTH IMPACTS OF THE COVID-19 PANDEMIC IN PEOPLE WITH AUTOIMMUNE DISEASES 2021 ,		2
286	Association of systemic lupus erythematosus autoantibody diversity with breast cancer protection. <i>Arthritis Research and Therapy</i> , 2021 , 23, 64	5.7	1
285	Reply. <i>Arthritis and Rheumatology</i> , 2021 , 73, 2149-2150	9.5	1
284	Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 1139-1145	5.3	1
283	COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION).. <i>Lupus</i> , 2021 , 9612033211062523	2.6	3
282	A prescription for exercise in systemic lupus erythematosus.. <i>Lupus</i> , 2021 , 9612033211061060	2.6	
281	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.. <i>Lupus Science and Medicine</i> , 2021 , 8,	4.6	5
280	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , 2020 ,	4.7	2
279	Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities. <i>Nature Communications</i> , 2020 , 11, 2197	17.4	20

278	Antiphospholipid syndrome. <i>Translational Research</i> , 2020 , 225, 70-81	11	14
277	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1734-1740	9.5	7
276	Low frequency of flares during pregnancy and post-partum in stable lupus patients. <i>Arthritis Research and Therapy</i> , 2020 , 22, 52	5.7	21
275	IL-1 Transcriptional Responses to Lipopolysaccharides Are Regulated by a Complex of RNA Binding Proteins. <i>Journal of Immunology</i> , 2020 , 204, 1334-1344	5.3	6
274	A Spatiotemporal Analysis of Organ-Specific Lupus Flares in Relation to Atmospheric Variables and Fine Particulate Matter Pollution. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1134-1142	9.5	8
273	Association of Urine sCD163 With Proliferative Lupus Nephritis, Fibrinoid Necrosis, Cellular Crescents and Intrarenal M2 Macrophages. <i>Frontiers in Immunology</i> , 2020 , 11, 671	8.4	13
272	Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. <i>Blood</i> , 2020 , 135, 239-251	2.2	72
271	Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	3
270	Integrated urine proteomics and renal single-cell genomics identify an IFN- γ response gradient in lupus nephritis. <i>JCI Insight</i> , 2020 , 5,	9.9	23
269	Patient ancestry significantly contributes to molecular heterogeneity of systemic lupus erythematosus. <i>JCI Insight</i> , 2020 , 5,	9.9	15
268	Association of African-American ethnicity and smoking status with total and individual damage index in systemic lupus erythematosus. <i>Clinical Rheumatology</i> , 2020 , 39, 365-373	3.9	2
267	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020 , 72, 1800-1808	4.7	7
266	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020 , 72, 658-666	9.5	11
265	Time to Lupus Low Disease Activity State in the Hopkins Lupus Cohort: Role of African American Ethnicity. <i>Arthritis Care and Research</i> , 2020 , 72, 225-232	4.7	8
264	Accelerating Medicines Partnership: Organizational Structure and Preliminary Data From the Phase 1 Studies of Lupus Nephritis. <i>Arthritis Care and Research</i> , 2020 , 72, 233-242	4.7	6
263	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020 , 106, 102340	15.5	15
262	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 356-362	2.4	18
261	New classification criteria for systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2020 , 32, 590-596	5.3	8

260	Loss of antiphospholipid antibody positivity post-thrombosis in SLE. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	1
259	Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	14
258	Characteristics of Antiphospholipid Antibody Positive Patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. <i>Arthritis Care and Research</i> , 2020 ,	4.7	13
257	Quantitative planar array screen of 1000 proteins uncovers novel urinary protein biomarkers of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1349-1361	2.4	13
256	Classical complement activation on human erythrocytes in subjects with systemic lupus erythematosus and a history of autoimmune hemolytic anemia. <i>Lupus</i> , 2020 , 29, 1179-1188	2.6	2
255	High-risk coronary plaque in SLE: low-attenuation non-calcified coronary plaque and positive remodelling index. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	4
254	Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. <i>Lupus</i> , 2020 , 961203320940776	2.6	12
253	Reply. <i>Arthritis and Rheumatology</i> , 2020 , 72, 2166	9.5	
252	Measures of Fatigue in Patients With Rheumatic Diseases: A Critical Review. <i>Arthritis Care and Research</i> , 2020 , 72 Suppl 10, 369-409	4.7	3
251	Cutaneous vasculitis in SLE. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	4
250	Glycosphingolipid-associated β 1,4 galactosyltransferase is elevated in patients with systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2020 , 7,	4.6	2
249	Predictors of osteonecrosis in systemic lupus erythematosus: A prospective cohort study. <i>Arthritis Care and Research</i> , 2020 ,	4.7	5
248	Blood Pressure Variability and Age-related Blood Pressure Patterns in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2020 , 47, 387-393	4.1	3
247	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2020 , 47, 72-81	4.1	21
246	Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, e90	2.4	6
245	Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy. <i>Arthritis and Rheumatology</i> , 2020 , 72, 448-453	9.5	50
244	Reply. <i>Arthritis and Rheumatology</i> , 2020 , 72, 694	9.5	
243	Pregnancy and Systemic Lupus Erythematosus. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020 , 64, 24-30	4.6	20

242	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020 , 72, 67-77	9.5	18
241	Human Lupus Plasma Pro-Atherogenic Effects on Cultured Macrophages Are Not Mitigated by Statin Therapy: A Mechanistic LAPS Substudy. <i>Medicina (Lithuania)</i> , 2019 , 55,	3.1	3
240	The immune cell landscape in kidneys of patients with lupus nephritis. <i>Nature Immunology</i> , 2019 , 20, 902-914	19.1	254
239	Hydroxychloroquine usage in US patients, their experiences of tolerability and adherence, and implications for treatment: survey results from 3127 patients with SLE conducted by the Lupus Foundation of America. <i>Lupus Science and Medicine</i> , 2019 , 6, e000317	4.6	11
238	Management strategies and future directions for systemic lupus erythematosus in adults. <i>Lancet, The</i> , 2019 , 393, 2332-2343	4.0	132
237	Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE. <i>Lupus Science and Medicine</i> , 2019 , 6, e000318	4.6	23
236	The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2019 , 49, 464-468	5.3	38
235	MICROPERIMETRY AS A SCREENING TEST FOR HYDROXYCHLOROQUINE RETINOPATHY: The Hard-Risk-1 Study. <i>Retina</i> , 2019 , 39, 485-491	3.6	4
234	Longitudinal profiling of human blood transcriptome in healthy and lupus pregnancy. <i>Journal of Experimental Medicine</i> , 2019 , 216, 1154-1169	16.6	33
233	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1297-1307	9.5	15
232	Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1125-1134	9.5	41
231	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , 2019 , 58, 1259-1267	3.9	5
230	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2019 , 106, 374-382	6.1	20
229	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019 , 71, 893-902	4.7	46
228	Preconceptional Cardiovascular Health and Pregnancy Outcomes in Women with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2019 , 46, 70-77	4.1	6
227	Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. <i>Journal of Thrombosis and Haemostasis</i> , 2019 , 17, 2069-2080	15.4	4
226	Anti-retinoblastoma Protein Antibodies: A New Specificity in Systemic Lupus Erythematosus Associated With Protection Against Lupus Nephritis. <i>ACR Open Rheumatology</i> , 2019 , 1, 287-291	3.5	1
225	Urinary pro-thrombotic, anti-thrombotic, and fibrinolytic molecules as biomarkers of lupus nephritis. <i>Arthritis Research and Therapy</i> , 2019 , 21, 176	5.7	7

224	Low hydroxychloroquine blood levels in patients who have had gastric bypass surgery. <i>Lupus Science and Medicine</i> , 2019 , 6, e000335	4.6	1
223	SLE Plasma Profiling Identifies Unique Signatures of Lupus Nephritis and Discoid Lupus. <i>Scientific Reports</i> , 2019 , 9, 14433	4.9	11
222	Differential Treatments Based on Drug-induced Gene Expression Signatures and Longitudinal Systemic Lupus Erythematosus Stratification. <i>Scientific Reports</i> , 2019 , 9, 15502	4.9	12
221	PD-1hiCXCR5- T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. <i>JCI Insight</i> , 2019 , 4,	9.9	76
220	Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2019 , 2019, 415-420	3.1	2
219	Fatigue Measurements in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2019 , 46, 1470-1477	4.1	14
218	Pericarditis in Lupus. <i>Cureus</i> , 2019 , 11, e4166	1.2	10
217	Rare Germline Mutations in Complement Regulatory Genes Make the Antiphospholipid Syndrome Catastrophic. <i>Blood</i> , 2019 , 134, 4-4	2.2	1
216	Development of a systemic lupus erythematosus cardiovascular risk equation. <i>Lupus Science and Medicine</i> , 2019 , 6, e000346	4.6	24
215	185 Baricitinib-associated changes in type I interferon gene signature during a 24-week phase 2 clinical SLE trial 2019 ,		2
214	199 Baricitinib in patients with systemic lupus erythematosus: results from a phase 2, randomized, double-blind, placebo-controlled study 2019 ,		2
213	Autoantibody clustering of lupus-associated pulmonary hypertension. <i>Lupus Science and Medicine</i> , 2019 , 6, e000356	4.6	5
212	Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes. <i>Arthritis and Rheumatology</i> , 2019 , 71, 411-419	9.5	25
211	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1010-1012	2.4	4
210	Systemic lupus erythematosus: Diagnosis and clinical management. <i>Journal of Autoimmunity</i> , 2019 , 96, 1-13	15.5	175
209	Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus. <i>BMC Medical Genomics</i> , 2019 , 12, 4	3.7	25
208	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2019 , 71, 281-289	9.5	31
207	Response to: 'Postpartum breastfeeding status' by Betzold. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e38	2.4	

206	The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository. <i>Arthritis Care and Research</i> , 2019 , 71, 134-141	4.7	23
205	Effect of pregnancy on disease flares in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 855-860	2.4	55
204	Renal Remission Status and Longterm Renal Survival in Patients with Lupus Nephritis: A Retrospective Cohort Analysis. <i>Journal of Rheumatology</i> , 2018 , 45, 671-677	4.1	22
203	A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. <i>Human Molecular Genetics</i> , 2018 , 27, 2392-2404	5.6	22
202	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018 , 45, 393-396	4.1	23
201	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018 , 57, 677-687	3.9	20
200	Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 549-555	2.4	73
199	Epidemiology of systemic lupus erythematosus: an update. <i>Current Opinion in Rheumatology</i> , 2018 , 30, 144-150	5.3	134
198	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018 , 70, 1478-1487	4.7	36
197	Contribution of Socioeconomic Status to Racial/Ethnic Disparities in Adverse Pregnancy Outcomes Among Women With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018 , 70, 230-235	4.7	18
196	Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index. <i>Rheumatology</i> , 2018 , 57, 125-133	3.9	8
195	A Prospective International Study on Adherence to Treatment in 305 Patients With Flaring SLE: Assessment by Drug Levels and Self-Administered Questionnaires. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 1074-1082	6.1	24
194	Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. <i>Arthritis Research and Therapy</i> , 2018 , 20, 133	5.7	26
193	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2018 , 392, 222-231	4.0	243
192	Autoimmune reactivity to malondialdehyde adducts in systemic lupus erythematosus is associated with disease activity and nephritis. <i>Arthritis Research and Therapy</i> , 2018 , 20, 36	5.7	9
191	Reply. <i>Arthritis and Rheumatology</i> , 2018 , 70, 2099	9.5	
190	Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. <i>Human Molecular Genetics</i> , 2018 , 27, 3813-3824	5.6	23
189	The SLE-key test serological signature: new insights into the course of lupus. <i>Rheumatology</i> , 2018 , 57, 1632-1640	3.9	9

188	Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. <i>Lupus Science and Medicine</i> , 2018 , 5, e000263	4.6	14
187	Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort. <i>Lupus Science and Medicine</i> , 2018 , 5, e000237	4.6	11
186	HMG-CoA Reductase Inhibitors Do Not Ameliorate Progressive Atherogenic Changes In Human Macrophages Treated With Systemic Lupus Erythematosus Patient Plasma: Implications For Statin Use and Novel Insight Into Systemic Lupus Erythematosus. <i>FASEB Journal</i> , 2018 , 32, 813.5	0.9	
185	Pauci-immune Glomerulonephritis in Systemic Lupus Erythematosus (SLE). <i>Cureus</i> , 2018 , 10, e2949	1.2	1
184	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2018 , 70, 1294-1302	4.7	13
183	Predictors of persistent disease activity and long quiescence in systemic lupus erythematosus: results from the Hopkins Lupus Cohort. <i>Lupus Science and Medicine</i> , 2018 , 5, e000287	4.6	7
182	Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus. <i>Immunity</i> , 2018 , 49, 725-739.e6	32.3	303
181	Enhancer RNA and NFB-dependent P300 regulation of ADAMDEC1. <i>Molecular Immunology</i> , 2018 , 103, 312-321	4.3	10
180	Rheumatoid Pachymeningitis: A Rare Complication of Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2018 , 45, 1325-1326	4.1	1
179	Comparison of Remission and Lupus Low Disease Activity State in Damage Prevention in a United States Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1790-1795	9.5	68
178	Stratification of Systemic Lupus Erythematosus Patients Into Three Groups of Disease Activity Progression According to Longitudinal Gene Expression. <i>Arthritis and Rheumatology</i> , 2018 , 70, 2025-2033	9.5	53
177	Cerebral Venous Thrombosis Mimicking a Discrete Brain Mass: A Case Report and Literature Review. <i>Case Reports in Rheumatology</i> , 2018 , 2018, 5862912	0.8	1
176	Reply. <i>Arthritis Care and Research</i> , 2017 , 69, 454	4.7	
175	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 554-561	2.4	175
174	Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 543-546	2.4	80
173	Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 534-542	2.4	71
172	Remission in systemic lupus erythematosus: durable remission is rare. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 547-553	2.4	59
171	Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort. <i>Lupus Science and Medicine</i> , 2017 , 4, e000192	4.6	34

170	Predictors of incident proteinuria among patients with SLE. <i>Lupus Science and Medicine</i> , 2017 , 4, e000200.6	12
169	Systemic Lupus Erythematosus and Pregnancy. <i>Rheumatic Disease Clinics of North America</i> , 2017 , 43, 215-226	2.4 54
168	Alterations in urinary collagen peptides in lupus nephritis subjects correlate with renal dysfunction and renal histopathology. <i>Nephrology Dialysis Transplantation</i> , 2017 , 32, 1468-1477	4.3 8
167	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017 , 8, 16021	17.4 171
166	The risk benefit ratio of glucocorticoids in SLE: have things changed over the past 40 years?. <i>Current Treatment Options in Rheumatology</i> , 2017 , 3, 164-172	1.3 17
165	Associates and predictors of pleurisy or pericarditis in SLE. <i>Lupus Science and Medicine</i> , 2017 , 4, e0002214.6	27
164	Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab. <i>Arthritis and Rheumatology</i> , 2017 , 69, 643-654	9.5 34
163	Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials. <i>Arthritis and Rheumatology</i> , 2017 , 69, 362-375	9.5 125
162	Progression of noncalcified and calcified coronary plaque by CT angiography in SLE. <i>Rheumatology International</i> , 2017 , 37, 59-65	3.6 14
161	Neuroimaging of translocator protein in patients with systemic lupus erythematosus: a pilot study using [C]DPA-713 positron emission tomography. <i>Lupus</i> , 2017 , 26, 170-178	2.6 14
160	Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. <i>Arthritis Research and Therapy</i> , 2017 , 19, 287	5.7 1
159	Clinical Outcomes Observed among Biopsy Proven Lupus Nephritis Patients Treated with Mycophenolate Mofetil as First-line Therapy. <i>Cureus</i> , 2017 , 9, e1907	1.2 1
158	Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 242-52	2.4 8
157	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016 , 55, 252-62	3.9 210
156	Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. <i>American Journal of Obstetrics and Gynecology</i> , 2016 , 214, 108.e1-108.e14	6.4 96
155	High-Resolution Analysis of Antibodies to Post-Translational Modifications Using Peptide Nanosensor Microarrays. <i>ACS Nano</i> , 2016 , 10, 10652-10660	16.7 12
154	Response to: 'Remission in SLE: the duration depends on multiple factors, including the definition' by Doria et al. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e78	2.4 1
153	Dr. Durcan, et al reply. <i>Journal of Rheumatology</i> , 2016 , 43, 1255	4.1

152	Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE. <i>Lupus Science and Medicine</i> , 2016 , 3, e000107	4.6	20
151	Development of Biomarker Models to Predict Outcomes in Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1955-63	9.5	27
150	Performance Characteristics of Commercial Immunoassays for the Detection of IgG and IgM Antibodies to β Glycoprotein I and an Initial Assessment of Newly Developed Reference Materials for Assay Calibration. <i>American Journal of Clinical Pathology</i> , 2016 , 145, 796-805	1.9	10
149	H3K4 tri-methylation breadth at transcription start sites impacts the transcriptome of systemic lupus erythematosus. <i>Clinical Epigenetics</i> , 2016 , 8, 14	7.7	26
148	Predictors of Incident Seizure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2016 , 43, 565-75	7.5	16
147	Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 2007-2013	2.4	12
146	Cytosolic 5'-Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases. <i>Arthritis Care and Research</i> , 2016 , 68, 66-71	4.7	71
145	Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. <i>Lupus Science and Medicine</i> , 2016 , 3, e000131	4.6	72
144	Longitudinal Evaluation of Lipoprotein Variables in Systemic Lupus Erythematosus Reveals Adverse Changes with Disease Activity and Prednisone and More Favorable Profiles with Hydroxychloroquine Therapy. <i>Journal of Rheumatology</i> , 2016 , 43, 745-50	4.1	42
143	SLE-key(\square) rule-out serologic test for excluding the diagnosis of systemic lupus erythematosus: Developing the ImmunArray iCHIP(\square). <i>Journal of Immunological Methods</i> , 2016 , 429, 1-6	2.5	16
142	Self-reactive IgE exacerbates interferon responses associated with autoimmunity. <i>Nature Immunology</i> , 2016 , 17, 196-203	19.1	98
141	PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1145-51	2.4	28
140	Significance of Lipid-Derived Reactive Aldehyde-Specific Immune Complexes in Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2016 , 11, e0164739	3.7	11
139	β 2-Glycoprotein Antibodies Activate the Alternative Pathway of Complement in Antiphospholipid Antibody Syndrome. <i>Blood</i> , 2016 , 128, 3818-3818	2.2	
138	Clinical Application of a Modular Genomics Technique in Systemic Lupus Erythematosus: Progress towards Precision Medicine. <i>International Journal of Genomics</i> , 2016 , 2016, 7862962	2.5	7
137	The Use of Poly-L-Lysine as a Capture Agent to Enhance the Detection of Antinuclear Antibodies by ELISA. <i>PLoS ONE</i> , 2016 , 11, e0161818	3.7	13
136	Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1964-9	9.5	18
135	Clinical significance and correlations between anti- β glycoprotein I IgA assays in antiphospholipid syndrome and/or systemic lupus erythematosus. <i>Clinica Chimica Acta</i> , 2016 , 460, 107-13	6.2	19

134	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , 2016 , 68, 1932-44	9.5	27
133	Association of Antibodies to Interferon-Inducible Protein-16 With Markers of More Severe Disease in Primary Sjögren's Syndrome. <i>Arthritis Care and Research</i> , 2016 , 68, 254-60	4.7	27
132	Response to Dr Nikpour's letter. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, e80	2.4	
131	Multiplex giant magnetoresistive biosensor microarrays identify interferon-associated autoantibodies in systemic lupus erythematosus. <i>Scientific Reports</i> , 2016 , 6, 27623	4.9	21
130	Antibody-Array-Based Proteomic Screening of Serum Markers in Systemic Lupus Erythematosus: A Discovery Study. <i>Journal of Proteome Research</i> , 2016 , 15, 2102-14	5.6	32
129	Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials. <i>Arthritis and Rheumatology</i> , 2016 , 68, 2184-92	9.5	29
128	A quantitative lateral flow assay to detect complement activation in blood. <i>Analytical Biochemistry</i> , 2015 , 477, 78-85	3.1	38
127	The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. <i>Autoimmunity Reviews</i> , 2015 , 14, 401-14	13.6	136
126	Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. <i>Annals of Internal Medicine</i> , 2015 , 163, 153-63	8	264
125	Coronary calcification in SLE: comparison with the Multi-Ethnic Study of Atherosclerosis. <i>Rheumatology</i> , 2015 , 54, 1976-81	3.9	26
124	Lupus Risk Variant Increases pSTAT1 Binding and Decreases ETS1 Expression. <i>American Journal of Human Genetics</i> , 2015 , 96, 731-9	11	31
123	Risk factors for cataracts in systemic lupus erythematosus (SLE). <i>Rheumatology International</i> , 2015 , 35, 701-8	3.6	22
122	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1837-47	9.5	77
121	Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins Lupus Cohort. <i>Lupus Science and Medicine</i> , 2015 , 2, e000066	4.6	86
120	Effect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus. <i>Rheumatology International</i> , 2015 , 35, 1687-92	3.6	16
119	Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus. <i>Clinical Immunology</i> , 2015 , 161, 157-62	9	8
118	Safety and Efficacy of Belimumab to Treat Systemic Lupus Erythematosus in Academic Clinical Practices. <i>Journal of Rheumatology</i> , 2015 , 42, 2288-95	4.1	58
117	Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence. <i>Journal of Rheumatology</i> , 2015 , 42, 2092-7	4.1	98

116	Monocyte enhancers are highly altered in systemic lupus erythematosus. <i>Epigenomics</i> , 2015 , 7, 921-35	4.4	20
115	An integrated extrapolation of long-term outcomes in systemic lupus erythematosus: analysis and simulation of the Hopkins lupus cohort. <i>Rheumatology</i> , 2015 , 54, 623-32	3.9	14
114	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1530-6	2.4	51
113	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1706-13	2.4	250
112	The Role of MicroRNAs and Human Epidermal Growth Factor Receptor 2 in Proliferative Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2015 , 67, 2415-26	9.5	31
111	Lupus anticoagulant, disease activity and low complement in the first trimester are predictive of pregnancy loss. <i>Lupus Science and Medicine</i> , 2015 , 2, e000095	4.6	24
110	BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year. <i>Lupus Science and Medicine</i> , 2015 , 2, e000063	4.6	15
109	Longitudinal analysis of peripheral blood T cell receptor diversity in patients with systemic lupus erythematosus by next-generation sequencing. <i>Arthritis Research and Therapy</i> , 2015 , 17, 132	5.7	40
108	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 138-42	2.4	83
107	Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2014 , 41, 300-9	4.1	118
106	American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort. <i>Journal of Rheumatology</i> , 2014 , 41, 875-80	4.1	17
105	Lupus nephritis susceptibility loci in women with systemic lupus erythematosus. <i>Journal of the American Society of Nephrology: JASN</i> , 2014 , 25, 2859-70	12.7	83
104	Prevention and management of co-morbidities in SLE. <i>Presse Medicale</i> , 2014 , 43, e187-95	2.2	21
103	14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. <i>Autoimmunity Reviews</i> , 2014 , 13, 917-30	13.6	186
102	Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis. <i>PLoS ONE</i> , 2014 , 9, e112545	3.7	26
101	Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials. <i>Lupus Science and Medicine</i> , 2014 , 1, e000031	4.6	53
100	Predictors of incident depression in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2014 , 41, 1823-33	4.1	46
99	End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. <i>Arthritis and Rheumatology</i> , 2014 , 66, 390-6	9.5	174

98	Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al. Reply. <i>Arthritis and Rheumatology</i> , 2014 , 66, 480	9.5	
97	Two functional lupus-associated BLK promoter variants control cell-type- and developmental-stage-specific transcription. <i>American Journal of Human Genetics</i> , 2014 , 94, 586-98	11	49
96	The SLE transcriptome exhibits evidence of chronic endotoxin exposure and has widespread dysregulation of non-coding and coding RNAs. <i>PLoS ONE</i> , 2014 , 9, e93846	3.7	91
95	Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2143-53		119
94	Cancer risk in systemic lupus: an updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , 2013 , 42, 130-5	15.5	194
93	Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2887-97		65
92	Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1865-71		101
91	Atherosclerosis in systemic lupus erythematosus. <i>Journal of Cardiovascular Pharmacology</i> , 2013 , 62, 255-62	5.2	45
90	Sifalimumab, a human anti-interferon- γ monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1011-21		193
89	Utility of antiphosphatidylserine/prothrombin and IgA antiphospholipid assays in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2013 , 40, 282-6	4.1	36
88	Increased expression of ADAMTS13 mRNA correlates with ischemic cerebrovascular disease in systemic lupus erythematosus patients. <i>SAGE Open Medicine</i> , 2013 , 1, 2050312113514404	2.4	1
87	Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. <i>Arthritis and Rheumatism</i> , 2012 , 64, 4021-8		162
86	Association of discoid lupus erythematosus with clinical manifestations and damage accrual in a multiethnic lupus cohort. <i>Arthritis Care and Research</i> , 2012 , 64, 704-12	4.7	23
85	Evaluation of TRAF6 in a large multiancestral lupus cohort. <i>Arthritis and Rheumatism</i> , 2012 , 64, 1960-9		45
84	Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2311-8		236
83	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2677-86		2688
82	European genetic ancestry is associated with a decreased risk of lupus nephritis. <i>Arthritis and Rheumatism</i> , 2012 , 64, 3374-82		42
81	Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. <i>American Journal of Epidemiology</i> , 2012 , 176, 708-19	3.8	192

80	Seasonal variation in the activity of systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2012 , 39, 1392-8	4.1	29
79	Semiquantified noncalcified coronary plaque in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2012 , 39, 2286-93	4.1	19
78	Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 1343-9	2.4	261
77	Biologics use in sle in 23 centers Data from the international registry for biologics in SLE. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, A9.1-A9	2.4	1
76	Clinical research in systemic lupus erythematosus: immediate relevance to clinical practice. <i>International Journal of Rheumatic Diseases</i> , 2011 , 14, 1-5	2.3	5
75	Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2011 , 377, 721-31	4.0	1206
74	Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. <i>Current Rheumatology Reports</i> , 2011 , 13, 77-80	4.9	143
73	A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2011 , 63, 3918-30		944
72	Association of IgA Anti-beta2 glycoprotein I with clinical and laboratory manifestations of systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2011 , 38, 64-8	4.1	59
71	Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus. <i>Rheumatology</i> , 2011 , 50, 2071-9	3.9	61
70	Depression and cognitive impairment in newly diagnosed systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2010 , 37, 2032-8	4.1	79
69	Noncalcified coronary plaque in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2010 , 37, 579-84	4.1	25
68	High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial. <i>Arthritis and Rheumatism</i> , 2010 , 62, 1487-93		37
67	Prevalence of flare and influence of demographic and serologic factors on flare risk in systemic lupus erythematosus: a prospective study. <i>Journal of Rheumatology</i> , 2009 , 36, 2476-80	4.1	47
66	Prednisone, lupus activity, and permanent organ damage. <i>Journal of Rheumatology</i> , 2009 , 36, 560-4	4.1	145
65	Novel evidence-based systemic lupus erythematosus responder index. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1143-51		318
64	A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1168-78		424
63	Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2009 , 36, 1195-9	4.1	131

62	Fibromyalgia, systemic lupus erythematosus (SLE), and evaluation of SLE activity. <i>Journal of Rheumatology</i> , 2009 , 36, 82-8	4.1	67
61	Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1784-8		49
60	Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2008 , 58, 2453-9		300
59	Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response. <i>Arthritis and Rheumatism</i> , 2008 , 58, 1789-95		15
58	Cognitive function in a systemic lupus erythematosus inception cohort. <i>Journal of Rheumatology</i> , 2008 , 35, 1776-81	4.1	35
57	Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. <i>Journal of Rheumatology</i> , 2008 , 35, 1567-75	4.1	23
56	The Hopkins Lupus Pregnancy Center: ten key issues in management. <i>Rheumatic Disease Clinics of North America</i> , 2007 , 33, 227-35, v	2.4	75
55	Monitoring systemic lupus erythematosus in standard clinical care. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007 , 21, 687-97	5.3	10
54	The TNFalpha locus is altered in monocytes from patients with systemic lupus erythematosus. <i>Clinical Immunology</i> , 2007 , 123, 74-81	9	60
53	Disease activity assessment in SLE: do we have the right instruments?. <i>Annals of the Rheumatic Diseases</i> , 2007 , 66 Suppl 3, iii61-4	2.4	40
52	Renal biopsy in lupus patients with low levels of proteinuria. <i>Journal of Rheumatology</i> , 2007 , 34, 332-5	4.1	68
51	Hydroxychloroquine in lupus pregnancy. <i>Arthritis and Rheumatism</i> , 2006 , 54, 3640-7		362
50	Predictors of survival in systemic lupus erythematosus. <i>Medicine (United States)</i> , 2006 , 85, 147-156	1.8	212
49	Management of antiphospholipid syndrome in pregnancy. <i>Rheumatic Disease Clinics of North America</i> , 2006 , 32, 591-607	2.4	37
48	Systemic lupus erythematosus: 2006 update. <i>Journal of Clinical Rheumatology</i> , 2006 , 12, 37-40	1.1	18
47	Flares in lupus: Outcome Assessment Trial (FLOAT), a comparison between oral methylprednisolone and intramuscular triamcinolone. <i>Journal of Rheumatology</i> , 2006 , 33, 57-60	4.1	24
46	Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2006 , 33, 1775-9	4.1	65
45	Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. <i>New England Journal of Medicine</i> , 2005 , 353, 2219-28	59.2	789

44	Review of classification criteria for systemic lupus erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2005 , 31, 245-54, vi	2.4	97
43	Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. <i>Annals of Internal Medicine</i> , 2005 , 142, 620-6	8	225
42	The impact of increased lupus activity on obstetric outcomes. <i>Arthritis and Rheumatism</i> , 2005 , 52, 514-21		290
41	Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups. <i>Arthritis and Rheumatism</i> , 2005 , 52, 2774-82		164
40	Combined oral contraceptives in women with systemic lupus erythematosus. <i>New England Journal of Medicine</i> , 2005 , 353, 2550-8	59.2	742
39	Cigarette smoking and the risk of systemic lupus erythematosus: a meta-analysis. <i>Arthritis and Rheumatism</i> , 2004 , 50, 849-57		236
38	The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort. <i>Thrombosis Research</i> , 2004 , 114, 593-5	8.2	85
37	Urine protein-to-creatinine ratio is a reliable measure of proteinuria in lupus nephritis. <i>Journal of Rheumatology</i> , 2004 , 31, 1557-9	4.1	54
36	Evidence-based management of thrombosis in the antiphospholipid antibody syndrome. <i>Current Rheumatology Reports</i> , 2003 , 5, 370-3	4.9	8
35	High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2003 , 48, 166-73		128
34	Immunosuppressive drug use in pregnancy. <i>Autoimmunity</i> , 2003 , 36, 51-6	3	67
33	Epidemiology of systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2002 , 16, 847-58	5.3	205
32	Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2002 , 46, 1820-9		132
31	Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2002 , 29, 2531-6	4.1	124
30	The DNA mismatch repair enzyme PMS1 is a myositis-specific autoantigen. <i>Arthritis and Rheumatism</i> , 2001 , 44, 389-96		61
29	Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2001 , 44, 2342-9		157
28	A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2001 , 44, 2350-7		128
27	Damage in systemic lupus erythematosus and its association with corticosteroids. <i>Arthritis and Rheumatism</i> , 2000 , 43, 1801-8		352

26	3' polymorphisms of ETS1 are associated with different clinical phenotypes in SLE. <i>Human Mutation</i> , 2000 , 16, 49-53	4.7	28
25	Treatment of the antiphospholipid antibody syndrome: progress in the last five years?. <i>Current Rheumatology Reports</i> , 2000 , 2, 256-61	4.9	12
24	Subcortical cognitive impairment in patients with systemic lupus erythematosus. <i>Journal of the International Neuropsychological Society</i> , 2000 , 6, 821-825	3.1	14
23	Hopkins Lupus Cohort. 1999 update. <i>Rheumatic Disease Clinics of North America</i> , 2000 , 26, 199-213, v	2.4	91
22	Assessing disease activity in SLE patients during pregnancy. <i>Lupus</i> , 1999 , 8, 677-84	2.6	135
21	Patterns of disease activity in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1999 , 42, 2682-8		128
20	Percutaneous vertebroplasty treatment of steroid-induced osteoporotic compression fractures. <i>Arthritis and Rheumatism</i> , 1998 , 41, 171-5		167
19	The polymorphic CYP17 allele is not found with increased frequency in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1998 , 41, 940-1		2
18	The Fc gammaRIIIA-158F allele is a risk factor for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1998 , 41, 1813-8		121
17	Oral contraceptives and systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1997 , 40, 797-803		99
16	The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1997 , 40, 809-13		505
15	A promoter polymorphism of tumor necrosis factor alpha associated with systemic lupus erythematosus in African-Americans. <i>Arthritis and Rheumatism</i> , 1997 , 40, 2207-11		138
14	Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. <i>Lancet, The</i> , 1996 , 348, 1120-4	4.0	315
13	The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1996 , 39, 363-9		1688
12	Mannose-binding protein genetic polymorphisms in black patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1996 , 39, 2046-51		144
11	Musculoskeletal complications of systemic lupus erythematosus in the Hopkins Lupus Cohort: an update. <i>Arthritis and Rheumatism</i> , 1995 , 8, 137-45		131
10	Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. <i>American Journal of Medicine</i> , 1994 , 96, 254-9	2.4	250
9	Coronary artery disease risk factors in the Johns Hopkins Lupus Cohort: prevalence, recognition by patients, and preventive practices. <i>Medicine (United States)</i> , 1992 , 71, 291-302	1.8	170

8	Risk factors for coronary artery disease in patients with systemic lupus erythematosus. <i>American Journal of Medicine</i> , 1992 , 93, 513-9	2.4	501
7	Hair product use in systemic lupus erythematosus. A case-control study. <i>Arthritis and Rheumatism</i> , 1992 , 35, 625-9		41
6	Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. <i>Arthritis and Rheumatism</i> , 1991 , 34, 1538-45		263
5	Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. <i>Arthritis and Rheumatism</i> , 1991 , 34, 937-44		234
4	Accuracy of creatinine clearance in measuring glomerular filtration rate in patients with systemic lupus erythematosus without clinical evidence of renal disease. <i>Arthritis and Rheumatism</i> , 1990 , 33, 277-80		6
3	The frequency of lupus anticoagulant in systemic lupus erythematosus. A study of sixty consecutive patients by activated partial thromboplastin time, Russell viper venom time, and anticardiolipin antibody level. <i>Annals of Internal Medicine</i> , 1987 , 106, 524-31	8	185
2	Antinuclear antibody, lupus anticoagulant, and anticardiolipin antibody in women with idiopathic habitual abortion. A controlled, prospective study of forty-four women. <i>Arthritis and Rheumatism</i> , 1987 , 30, 601-6		154
1	Rheumatologic Disorders in Pregnancy209-222		